A better approach may therefore be the adoption of non-exclusive incentive regimes (i.e. compensatory liability) for new uses of known products, as discussed above. The original patent would comprise all uses, even those not known to the patentee at the time of filing the application. In countries where generic producers are capable of discovering new uses of patented pharmaceuticals, a government may favour the implementation of use-bound claims to provide generic producers some freedom to operate outside the original patent claims, in combination with provisions on “dependent patent” or public interest compulsory licenses, as outlined above. In addition, in order to minimize the risk of blocking effects, the protection of new uses of known products could be limited to nonexclusive models, such as a compensatory liability regime, recommended above. Due to the fact that such process claims may not cover all possible ways of manufacturing the resulting product, competitors are free to make the (pharmaceutical) product through a process that has not been claimed.